Investigating the combined effect of endostatin along with ‎endometrial stem cells expressing TSP-1 anti-angiogenic gene on ‎angiogenic induce factors on the treatment of prostate cancer in rats

Prostate cancer is the second leading cause of cancer deaths in men. Androgen ‎deprivation therapy has been identified to induce oxidative stress in prostate cancer, ‎leading to reactivation of androgen receptor (AR) signaling. Thus, antioxidant therapies ‎have gained attention as adjuvants for this cancer. Here, we report for the first time that ‎endostatin along with endometrial stem cells expressing TSP-1 anti-angiogenic gene ‎improved androgen- phenotype and genotype in rats prostate cancer cells.‎‏ ‏Forty male ‎rats (n=8) weighing approximately 95-100 g were purchased from Pasteur Inistitute of ‎Tehran . Animals were suffered to prostate cancer by injecting LNCaP cell line for 12 ‎weeks. Prostate cancer animals were immediately received endostatin for 28 days. ‎Prostate cancer animals were received stem cell containing the Tsp-1 anti-angiogenesis ‎gene. Histological examinations were measured. The levels of IL8 and VEGF serum ‎were assayed.‎‏ ‏In group receiving cells and drug, amount and height of acinus wall folds ‎decreased compared to the patient group and the shape of the vesicles was clear and the ‎epithelial lining were cohesive and regular. The levels of IL8 and VEGF serum were ‎significantly decreased in combination group than to prostate cancer group (P≤0.01). ‎